Radiopharmaceutical developer Actinium Pharmaceuticals is highlighting six research abstracts accepted for presentation at this week's Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 annual meeting in Chicago.
The abstracts include three oral presentations and three poster presentations on the company's technology for targeted radiotherapies in cancer patients. The abstracts include the following (all times presented in central time):
- "Machine learning applications to optimize dosimetric imaging of I-131 apamistamab for bone marrow conditioning in relapsed/refractory acute myeloid leukemia (R/R AML);" Session: New Developments in Radiopharmaceutical Therapy; June 25, 5 p.m. to 6:15 p.m.
- "Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I-131 apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia (R/R AML): Safety and efficacy results from the pivotal phase 3 SIERRA trial;" Session: Hematologic Malignancies; June 26, 12:45 p.m. to 2 p.m.
- "Administration and radiation safety of high-dose Iomab-B (I-131 apamistamab) demonstrated in multiple clinical settings: Experience from the large multicenter phase 3 SIERRA trial for targeted conditioning of patients with relapsed/refractory AML;" Session: Hematologic Malignancies; June 26, 12:35 p.m. to 2 p.m.
- "Organ-specific dosimetry to estimate potential toxicity thresholds of Actimab-A (lintuzumab Ac-225) used in combination with venetoclax in relapsed/refractory AML;" Track: Molecular Targeting Probes; June 25, 6:30 p.m. to 8:30 p.m.
- "Relative biological effectiveness of antibody radioconjugates (ARCs): In vitro dosimetric evaluation to streamline pre-clinical decision-making;" Track: Oncology, Basic and Translational; June 27, 12:30 p.m. to 2 p.m.
- "Streamlining personalized dosimetry for I-131 apamistamab using a Co-57 sheet source to circumvent the need for radionuclide-specific attenuation correction;" Track: Molecular Targeting Probes-Radioactive & Nonradioactive; June 27, 12:30 p.m. to 2 p.m.
